• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Injectable activated carbon suspensions are proposed for the presurgical marking of nonpalpable mammary pathologies for the purpose of achieving better diagnosis and treatment. These are suspensions that flow freely and without the formation of obstructing aggregates in the needles used during their application, with carbon particles of micron granulometry limited to less than 50μ and preferably between 2μ and 6μ in concentration of approximately 4.0% p/v in saline aqueous medium. A process is also proposed for preparing said compositions.
    公开号:US20010001038A1
    申请号:US09/731,336
    申请日:2000-12-06
    公开日:2001-05-10
    发明作者:Pedro Matianich；Juliana Gabor
    申请人:Laboratorios Temis；
    IPC主号:A61K33-44
    专利说明:
    [1] 1. The present invention relates to “carbon marking” of the breast for the purpose of localizing and delimiting histologically anomalous zones revealed by other techniques, such as echographic or radiographic, thus making possible more convenient and safer surgical access from the standpoint of precision of diagnosis and treatment and of aesthetic considerations with the mammary tissues undergoing surgery.
    [2] 2. Among the presurgical techniques of delimitation of nonpalpable mammary lesions, carbon marking forms part of the set of techniques whose application requires operating on the breast in minimally invasive form, for example, through the insertion of a needle to discharge the carbon in the zone investigated under radiographic or echographic monitoring.
    [3] 3. Other techniques of this group include marking using wires bent at one of their ends (hooks or harpoons) which are inserted in the mammary tissue using a tubular piece for guiding and positioning in relation to the target (lesion) under radiographic monitoring. Another technique of said group involves the injection of organic dye solutions, such as methylene blue or toluidine blue, for purposes of demarcating the zone to be studied.
    [4] 4. No method of presurgical demarcation of nonpalpable mammary lesions, whether noninvasive or minimally invasive, is free of defects: the noninvasive methods, which basically involve the use of measurements from reference points (the nipple, for example) and marking of the skin, raise the possibility of unreliable markings and the ultimate results entail the risk of either overly wide or incomplete exeresis, with the possibility in both cases of mammary disfiguration.
    [5] 5. In the use of minimally invasive techniques, the risks are in relation to the nature of the instrument used. In the case of the hook, for examples although it is more precise than the previous technique, the instrument can possibly be displaced, with the formation of visible lesions, such as localized hemorrhages and hematomas.
    [6] 6. Marking employing solutions of organic dyes like methylene blue or toluidine blue entails the need for rapid continuation of the diagnostic-therapeutic procedure, in view of the possibility of migration, diffusion and degradation of this type of dye.
    [7] 7. The use of carbon in turn requires careful choice of the preparation, as to its granulometry (particle size) and needle gage, in combination with a degree of skill in handling the injection device. All of these measures are aimed at preventing obstruction of the needle and promoting release of a continuous flow without interruptions, even in the course of extraction of the needle.
    [8] 8. With respect to the latter technique (carbon marking), injectable suspensions of 4% carbon in an aqueous medium are used and they are administered by injection with needles in the order of 20G.
    [9] 9. This technique has met with quick acceptance thanks to its reduced cost and the overcoming of disadvantages usually present with other techniques, such as lack of precision, displacement of the marking instrument and rapid degradation, among other things. The use of carbon as presurgical marker, on the other hand, offers among its advantages prolonged permanence in the zone marked, with color and limits well differentiated and, not being radiopaque, neither the radiology of the specimen nor the histopathological examination of same being altered. Furthermore, suspensions of carbon particles in an aqueous medium are involved, which is physiologically appropriate.
    [10] 10. The different techniques of presurgical localization of nonpalpable mammary lesions are described in the specialized bibliography (1) (2).
    [11] 11. It is clear from what has been summarized in the foregoing text that presurgical mammary marking with aqueous carbon solutions is considered an extremely useful technique from the operational as well as economical standpoint, in spite of its possible limitations, such as obstruction of needles because of inadequate particle size and collapse or discontinuity of the discharge flow or stream.
    [12] 12. This invention makes it possible to resolve the negative aspects mentioned by providing activated carbon suspensions of adequate particle size within precise limits, resulting in an operational improvement of the technique, being less difficult, more reliable and precise for the physician and more comfortable for the patient. THE INVENTION
    [13] 13. The main object of the present invention consists of injectable activated carbon solutions for the presurgical marking of mammary lesions, which comprise, in aqueous suspension, ground activated carbon having, all together, particles smaller than 50μ in size and preferably between 2μ and 6μ. Said compositions flow freely and without the formation of obstructing aggregates in the needles during their application.
    [14] 14. The process of preparation of activated carbon of the aforementioned granulometry is also the object of the invention, useful for formulating said injectable compositions, preferably by grinding the activated carbon in a cylindrical rod mill, whose surface has a sufficient hardness for obtaining the effect desired, like, for example, those of zirconia (ZrO2). DETAILED DESCRIPTION OF THE INVENTION
    [15] 15. Innovations in the art of preparing compositions for the presurgical marking of mammary lesions are combined in this invention, using aqueous suspensions of activated carbon as marker for identifying and delimiting the zone to be operated on, namely:
    [16] 16. the selection of an optimum particle size of carbon for formulating compositions that flow freely and without the formation of obstructing aggregates in the needles used during their application;
    [17] 17. the selection and relationship of the means making it possible to obtain and use activated carbon of that optimal particle size from the functional standpoint.
    [18] 18. Said optimal particle size is clearly attainable according to this invention by processing the activated carbon preferably in roll (or rod) mills whose operating surface has sufficient hardness. Included within said range, among others, is zirconium oxide—zirconia (ZrO2)—with a hardness of 1160 units on the Knoop Scale, which is preferably applicable as a component of the body or surface of said rods. The use of this type of mill is a preferred aspect of the present invention. Even more preferable is the combination of the grinding of activated carbon using said rods of zirconia (or coated with zirconia) in chambers or drums whose interior surface is polyurethane. With the combination of these two factors, grinding and abrasive surfaces of zirconia and polyurethane coating of the grinding chamber, the profile of distribution of particles sizes shown on the graph of FIG. 1 of injectable compositions for the presurgical marking of mammary lesions is obtained.
    [19] 19. Other objects of the invention are: the methods for marking histologically abnormal mammary zones by injecting effective quantities of activated carbon of particle size less than 50μ, and preferably between 2μ and 6μ, in aqueous suspension and dosage form used in said method. DESCRIPTION OF THE FIGURES
    [20] 20.FIG. 1 corresponds to the graph of the profile of distribution of particle sizes of the injectable composition obtained in this invention, which was determined by using a Series 2600 Malvern Laser unit by the Laser Radiation Scattering method.
    [21] 21. It is observed that the average value of 4.46μ (D[v,0.5]) comes within the preferred range of 2μ to 6μ, there being no particles with values higher than 50μ.
    [22] 22.FIG. 2 corresponds to a graph similar to that of FIG. 1 of the injectable composition obtained without having undergone the grinding process, which was determined by using the same equipment described above.
    [23] 23. It is observed that the average value of 31.85 μ (D[v,0.5]) is outside the preferred range of 2μ to 6μ, particles existing with values higher than 50μ (and even exceeding 300μ).
    [24] 24. In the following example included by way of illustration, a preferred embodiment is described for obtaining activated carbon of granulometry conforming to the present invention. DESCRIPTION OF THE MANUFACTURING PROCESS
    [25] 25. 1. In a stainless steel container of 5-lt capacity, equipped with means of stirring, place 1.2 lt of distilled water prefiltered through a membrane of 0.45μ and depyrogenating plate.
    [26] 26. 2. Connect a helical agitator and add sodium chloride. Stir until dissolving it completely.
    [27] 27. 3. Add the surface-active agent and stir until dissolving it completely.
    [28] 28. 4. Add the activated carbon and stir until dispersing it completely.
    [29] 29. 5. Transfer the carbon suspension formed to an appropriate mill.
    [30] 30. 6. Grind for approximately 30 hours.
    [31] 31. 7. Place the ground suspension in a sterile glass vessel of 9-lt capacity and fill to 5 lt with distilled water filter through a 0.45μ membrane and depyrogenating plate.
    [32] 32. 8. Stir for 15 minutes.
    [33] 33. 9. Fractionate in Class II neutral glass vial flasks to a proper volume.
    [34] 34. 10. Plug the flasks with butyl stoppers and aluminum auxiliary cover.
    [35] 35. 11. Sterilize in autoclave at 121° C. for 20 minutes.
    权利要求:
    Claims (10)
    [1" id="US-20010001038-A1-CLM-00001] 1. Injectable activated carbon compositions, for application in presurgical marking of mammary lesions, characterized in that they comprise, in aqueous suspension, activated carbon ground and graded to a granulometry with particles not exceeding 50μ, in free-flowing aqueous suspension and without formation of obstructing deposits during their discharge.
    [2" id="US-20010001038-A1-CLM-00002] 2. Compositions in accordance with
    claim 1 , characterized in that the aqueous medium comprises 0.7 to 1.5% p/v of sodium chloride and 4.0% p/v of activated carbon of said granulometry.
    [3" id="US-20010001038-A1-CLM-00003] 3. Compositions in accordance with
    claim 1 , characterized in that the ground activated carbon is activated carbon ground in rod mills of zirconium oxide or the like and in grinding chambers coated with polyurethane for at least 30 hours.
    [4" id="US-20010001038-A1-CLM-00004] 4. Compositions in accordance with
    claims 1 to
    3 , characterized in that they comprise 0.3-1.0% p/v of a surface-active agent.
    [5" id="US-20010001038-A1-CLM-00005] 5. Dosage forms for application in presurgical marking of mammary lesions, characterized in that they include proportioned quantities of the composition of
    claim 1 in sterile units.
    [6" id="US-20010001038-A1-CLM-00006] 6. Process for preparing activated carbon of selective granulometry, for formation of the compositions of
    claim 1 , characterized in that it consists of grinding charges of activated carbon in a cylindrical rod mill, in a grinding chamber coated with a nonabrasive lining, for a period in the order of 25 to 60 hours.
    [7" id="US-20010001038-A1-CLM-00007] 7. Process in accordance with
    claim 1 , characterized in that said rods are made of zirconium oxide or the like and the coating is polyurethane.
    [8" id="US-20010001038-A1-CLM-00008] 8. Process in accordance with
    claim 1 , characterized in that the grinding time is in the order of 30 hours.
    [9" id="US-20010001038-A1-CLM-00009] 9. Use of activated carbon having a profile of distribution of particle sizes in the order of 2μ to 6μ and no particle greater than 50μ, originating from the grinding of activated carbon in accordance with the process of
    claim 6 , characterized in that it consists of preparation of the injectable compositions of
    claim 1 and the dosage forms of
    claim 5 respectively.
    [10" id="US-20010001038-A1-CLM-00010] 10. Method for marking histologically anomalous zones of the breast, characterized in that it consists of injecting effective quantities of the composition of
    claim 1 .
    类似技术:
    公开号 | 公开日 | 专利标题
    Castillo et al.1990|Intracranial ganglioglioma: MR, CT, and clinical findings in 18 patients.
    US6333971B2|2001-12-25|Fiducial marker
    EP1249207B1|2006-01-04|Fiducial marker
    S. Paleologos, M. Thom, DGT Thomas2000|Spinal neurenteric cysts without associated malformations. Are they the same as those presenting in spinal dysraphism?
    KR20080067333A|2008-07-18|Imaging agents comprising silicon
    Lundin et al.1992|MRI of pituitary macroadenomas with reference to hormonal activity
    Aquilino et al.2006|Odontogenic myxoma in the maxilla: a case report and characteristics on CT and MR
    ISHIKAWA et al.2000|Intracerebellar Penetrating Injury and Abscess Due to a Wooden Foreign Body—Case Report—
    US6409989B2|2002-06-25|Injectable carbon compositions in stable aqueous suspension; method for preparing them and method of presurgical marking in the investigation of nonpalpable mammary pathologies by applying said compositions
    Vaquero et al.1988|Symptomatic glial cysts of the pineal gland
    D'Haen et al.1995|Chordoma of the lower cervical spine
    Bretschneider et al.1999|Squamous cell carcinoma arising in an intradiploic epidermoid cyst
    Dahlgren et al.1970|Aspiration biopsy diagnosis of neurogenous mediastinal tumours
    Meier et al.2008|Detection of postoperative granulation tissue with an ICG-enhanced integrated OI-/X-ray System
    Garagnani et al.2008|Primary hydatid cyst of the root of the thigh: a case report and review of the literature
    Kocasarac et al.2020|Assessment of signal-to-noise ratio and contrast-to-noise ratio in 3 T magnetic resonance imaging in the presence of zirconium, titanium, and titanium-zirconium alloy implants
    Kumar et al.2007|Lhermitte–Duclos disease
    Leggett et al.1998|Blood‐brain barrier and blood volume imaging of cerebral glioma using functional CT: A pictorial review
    Kremer et al.1996|MR imaging of residual tumor tissue after transsphenoidal surgery of hormone-inactive pituitary macroadenomas: a prospective study
    Winter et al.2014|Spindle cell hemangioendothelioma of the sacrum: case report
    Bonafe et al.1981|Relative value of computed tomography and hypocycloidal tomography in the diagnosis of pituitary microadenoma a radio-surgical correlative study
    Fargason et al.1982|A three-dimensional and volume determination of tumors of the cerebellopontine angle
    Pereyra-Rodríguez et al.2010|Nasal glial heterotopia |
    Lombardo et al.1996|Kaposi's sarcoma with primary bone lesions in an HIV‐seronegative man
    Cihangiroglu et al.2001|Intraosseous sacral myxopapillary ependymoma and the differential diagnosis of sacral tumors
    同族专利:
    公开号 | 公开日
    BR9906240A|2002-07-23|
    US6409989B2|2002-06-25|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US11058780B2|2016-05-20|2021-07-13|Technical University Of Denmark|Palpable marker composition|ZA815721B|1980-08-26|1983-01-26|Boyd Terence Keogh|Bagasse residue filter materials and activated carbon products and methods of manufacturing same|
    US5332524A|1992-04-20|1994-07-26|Valkyrie Scientific Proprietary, L.C.|Methods for dissolving water soluble polymers and compositions using same|US7574263B2|2003-01-31|2009-08-11|Second Sight Medical Products, Inc.|Pixel re-mapping for visual prosthesis|
    法律状态:
    2002-06-06| STCF| Information on status: patent grant|Free format text: PATENTED CASE |
    2005-12-27| FPAY| Fee payment|Year of fee payment: 4 |
    2009-12-24| FPAY| Fee payment|Year of fee payment: 8 |
    2014-01-31| REMI| Maintenance fee reminder mailed|
    2014-02-18| FPAY| Fee payment|Year of fee payment: 12 |
    2014-02-18| SULP| Surcharge for late payment|Year of fee payment: 11 |
    优先权:
    申请号 | 申请日 | 专利标题
    ARP990103112||1999-06-28||
    AR990103112||1999-06-28||
    AR9903112||1999-06-28||
    US47936100A| true| 2000-01-07|2000-01-07||
    US09/731,336|US6409989B2|1999-06-28|2000-12-06|Injectable carbon compositions in stable aqueous suspension; method for preparing them and method of presurgical marking in the investigation of nonpalpable mammary pathologies by applying said compositions|US09/731,336| US6409989B2|1999-06-28|2000-12-06|Injectable carbon compositions in stable aqueous suspension; method for preparing them and method of presurgical marking in the investigation of nonpalpable mammary pathologies by applying said compositions|
    [返回顶部]